Mount Sinai Hospital researchers have become the first in the US to use artificial intelligence (AI) to analyse patients with Covid-19.

The algorithm uses imaging and clinical data to detect Covid-19, based on how lung disease looks in computed tomography (CT) scans of the chest. These scans are combined with patient information such as symptoms, age, bloodwork results and possible contact with infected individuals.

Mount Sinai director of biomedical engineering and imaging Dr Zahi Fayad said: “Imaging can help give a rapid and accurate diagnosis – lab tests can take up to two days, and there is the possibility of false negatives – meaning imaging can help isolate patients immediately if needed, and manage hospital resources effectively.

“The high sensitivity of our AI model can provide a ‘second opinion’ to physicians in cases where CT is either negative (in the early course of infection) or shows nonspecific findings, which can be common. It’s something that should be considered on a wider scale, especially in the United States, where currently we have more spare capacity for CT scanning than in labs for genetic tests.”

Currently, CT scans are not widely used for Covid-19 diagnosis in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.